No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Sunday, October 12, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause

by TheAdviserMagazine
3 months ago
in Business
Reading Time: 3 mins read
A A
Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause
Share on FacebookShare on TwitterShare on LInkedIn


Sarepta Therapeutics’ (SRPT) stock has been hammered in the past week after the company was forced to pause shipments of its top-selling Duchenne muscular dystrophy (DMD) therapy Elevidys — throwing the future of the company into question.

Elevidys netted $821 million of the company’s $1.78 billion in 2024 revenue and contributed to more than 50% of the company’s $513 million in second quarter revenue this year. It’s the company’s top-selling product. It’s why seven analysts have downgraded the stock since Friday, including Bank of America’s Tazeen Ahmad on Wednesday.

Ahmad downgraded the stock to Underperform and revised the firm’s price target to $10 from $20. The stock is currently trading at $13.90 per share and closed down more than 2% on Wednesday.

Sarepta “has requested a meeting with FDA and might have more visibility on length of the pause once FDA responds to their submission for a revised label,” Ahmad wrote in a note to clients. “In short, we think this could impact the Elevidys brand further, limiting uptake following highly focused media attention as well as a renewed chance of Elevidys being removed from the US market.”

Leerink Partners downgraded the stock last week from Outperform to Market Perform. Analyst Joseph Schwartz wrote in a note to clients on Monday that how long the pause lasts is important for future modeling.

“This decision is also roughly aligned with our published SRPT model, which assumes a significant slowing of sales in the third quarter, zero sales in the fourth quarter, and a resumption of shipments in early 2026,” Schwartz wrote. “We lack visibility into how long this pause may last, or what the intermediate scenarios are from here (e.g., a narrower approval).”

The stock now has five Buy, 17 Hold, and four Sell ratings.

In this photo illustration, a Sarepta Therapeutics logo is seen on a smartphone and a pc screen. (Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) · SOPA Images via Getty Images

The technology to deliver the therapy in Elevidys is at the center of the issue facing the company. A 51-year-old, late-stage patient in a phase 1 trial of a different muscular dystrophy therapy, known only by its trial name, SRP-9004, died from liver toxicity last month, but Sarepta failed to disclose the death — even as it announced it was discontinuing the trial as part of a restructuring last week.

That began the domino effect of downgrades and the stock sell-off as analysts questioned why the company had kept quiet. On a call with investors Friday, CEO Doug Ingram defended his reasoning for not mentioning it.

“We did not discuss this matter in our call on Wednesday because it was neither material nor central to the topics at hand on Wednesday,” Ingram said.

繼續閱讀

In a note following the call, Leerink’s Schwartz wrote, “Is This Material?!? All Credibility Lost.”

It’s the third death linked to a gene therapy from the company this year and a reason why the FDA previously required the company to add new warning labels to Elevidys, which is part of the pause in shipments currently.

But now, the company’s future is in flux as its revenue stream has been paused for an undetermined amount of time.

Jefferies analyst Andrew Tsai, one of the few who has maintained a Buy rating, said the company could defend the therapy as sicker and older patients have been more negatively impacted, while younger patients who are still able to move independently have benefited.

“Prior to the third death, SRPT’s internal stress tests suggested the DMD franchise could ‘floor’ at $1.4B annually into 2027, including $500M+ for Elevidys in ambulatory,” Tsai wrote in a note to clients Sunday. “For Elevidys, one can point to how the deaths have occurred only in older patients.”

“More cost reductions is possible too,” Tsai noted of how Sarepta could end up handling the hit.

Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem.

Click here for in-depth analysis of the latest health industry news and events impacting stock prices



Source link

Tags: downgradesElevidysfacesMultiplePauseQuestionsSareptaSolvencystock
ShareTweetShare
Previous Post

Student loan cap poses planning problems for advisors

Next Post

The Chowder Rule | How To Calculate The Chowder Number

Related Posts

edit post
oil prices: Oil rebounds 1% after sharp losses on US-China tensions

oil prices: Oil rebounds 1% after sharp losses on US-China tensions

by TheAdviserMagazine
October 12, 2025
0

SINGAPORE -Oil prices clawed back some gains on Monday after hitting five-month lows in the previous session as investors hoped...

edit post
Trump warns Russia he may send Tomahawk missiles to Ukraine if war isn’t settled soon

Trump warns Russia he may send Tomahawk missiles to Ukraine if war isn’t settled soon

by TheAdviserMagazine
October 12, 2025
0

President Donald Trump on Sunday warned Russia that he may send Ukraine long-range Tomahawk missiles if Moscow doesn’t settle its war there soon —...

edit post
Oracle’s AI empire runs on Nvidia, but the numbers don’t add up

Oracle’s AI empire runs on Nvidia, but the numbers don’t add up

by TheAdviserMagazine
October 12, 2025
0

Oracle is unafraid when it comes to hedging big bets. The company is making a career out of reinventing itself...

edit post
SA Asks: What’s the best telecom play right now? (T:NYSE)

SA Asks: What’s the best telecom play right now? (T:NYSE)

by TheAdviserMagazine
October 12, 2025
0

Oct. 12, 2025 4:50 PM ETAT&T Inc. (T) Stock, VZ Stock, UNIT StockCMCSA, VOD, BCE, AMT, TMUS, DTEGY, CHTR, FYBRBy:...

edit post
North Korea unveils new intercontinental ballistic missile that may be tested in coming weeks

North Korea unveils new intercontinental ballistic missile that may be tested in coming weeks

by TheAdviserMagazine
October 12, 2025
0

At a massive military parade attended by foreign leaders, North Korean leader Kim Jong Un rolled out his nuclear-armed military’s most powerful...

edit post
5 Retirement Lessons I Wish I Knew in My 40s, From a Multimillionaire

5 Retirement Lessons I Wish I Knew in My 40s, From a Multimillionaire

by TheAdviserMagazine
October 12, 2025
0

According to a new survey by brokerage Charles Schwab, 57% of U.S. 401(k) plan participants admitted that inflation is a...

Next Post
edit post
The Chowder Rule | How To Calculate The Chowder Number

The Chowder Rule | How To Calculate The Chowder Number

edit post
Bianca Ferguson on Empowering Growth Through Technology

Bianca Ferguson on Empowering Growth Through Technology

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
Tips to Apply for Mental Health SSDI Without Therapy

Tips to Apply for Mental Health SSDI Without Therapy

September 19, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
Venezuela’s Opposition Used UN Meeting to Lobby for US Coup

Venezuela’s Opposition Used UN Meeting to Lobby for US Coup

0
edit post
Here’s What’s Next For Bitcoin And Ethereum

Here’s What’s Next For Bitcoin And Ethereum

0
edit post
7 Ways to Spot an AARP Scam Before It’s Too Late

7 Ways to Spot an AARP Scam Before It’s Too Late

0
edit post
oil prices: Oil rebounds 1% after sharp losses on US-China tensions

oil prices: Oil rebounds 1% after sharp losses on US-China tensions

0
edit post
Health Care Consolidation Continues to Raise Concerns

Health Care Consolidation Continues to Raise Concerns

0
edit post
SA Asks: What’s the best telecom play right now? (T:NYSE)

SA Asks: What’s the best telecom play right now? (T:NYSE)

0
edit post
oil prices: Oil rebounds 1% after sharp losses on US-China tensions

oil prices: Oil rebounds 1% after sharp losses on US-China tensions

October 12, 2025
edit post
XRP ETF Countdown Heats up as SEC Filings Surge and Bulls Eye Breakout Rally

XRP ETF Countdown Heats up as SEC Filings Surge and Bulls Eye Breakout Rally

October 12, 2025
edit post
Trump warns Russia he may send Tomahawk missiles to Ukraine if war isn’t settled soon

Trump warns Russia he may send Tomahawk missiles to Ukraine if war isn’t settled soon

October 12, 2025
edit post
Oracle’s AI empire runs on Nvidia, but the numbers don’t add up

Oracle’s AI empire runs on Nvidia, but the numbers don’t add up

October 12, 2025
edit post
SA Asks: What’s the best telecom play right now? (T:NYSE)

SA Asks: What’s the best telecom play right now? (T:NYSE)

October 12, 2025
edit post
Oracle (ORCL): Cloud-Gigant in Lauerstellung!

Oracle (ORCL): Cloud-Gigant in Lauerstellung!

October 12, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • oil prices: Oil rebounds 1% after sharp losses on US-China tensions
  • XRP ETF Countdown Heats up as SEC Filings Surge and Bulls Eye Breakout Rally
  • Trump warns Russia he may send Tomahawk missiles to Ukraine if war isn’t settled soon
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.